Trial Profile

A trial of NV-VPAC1™ Liquid Biopsy Diagnostic Test

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NLS VPAC1 (Primary)
Indications Advanced breast cancer; Cancer; Prostate cancer; Urogenital cancer
Focus Diagnostic use

08 Jan 2024 New trial record
03 Jan 2024 According to a NuView Life Sciences media release, following approval from COFEPRIS, NuView plans to immediately request U.S. Food and Drug Administration (FDA) reciprocal recognition of NV-VPAC1™ Liquid Biopsy Diagnostic Test for commercial use in the United States.
03 Jan 2024 According to a NuView Life Sciences media release, trial is planned to commence in early 2024 in Guadalajara and Mexico City with approval from Mexico's Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS) anticipated in early 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com